Clinical Trials Browser

Phase 3 × Active not recruiting × Nasopharyngeal Carcinoma × Clear all

Nasopharyngeal Carcinoma

NCT06118333 2025-09-30

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

386 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04384627 2025-09-04

NPC-GTV

Phase 3 Active not recruiting

445 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04907370 2025-07-16

DIAMOND

Phase 3 Active not recruiting

532 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05294172 2025-05-30

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

295 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

381 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

296 enrolled 1 FDA

Head & Neck

Nasopharyngeal Carcinoma

NCT05304468 2025-03-21

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Phase 3 Active not recruiting

452 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05587374 2025-01-23

GEMSTONE

Phase 3 Active not recruiting

490 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

468 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

166 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02460887 2024-12-03

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Phase 3 Active not recruiting

236 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05211232 2024-04-18

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

450 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03306121 2023-05-22

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

322 enrolled

Head & Neck

Nasopharyngeal Carcinoma

Clinical Trials

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

NPC-GTV

DIAMOND

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

GEMSTONE

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma